TN2011000433A1 - Alpha -4-beta-7heterodimer specific antagonist antibody - Google Patents

Alpha -4-beta-7heterodimer specific antagonist antibody

Info

Publication number: TN2011000433A1
Authority: TN; Tunisia
Prior art keywords: beta; alpha; antagonist antibody; specific antagonist; specific
Prior art date: 2009-03-20

Application number

TN2011000433A

Other languages

English (en)

Inventor

Hailing Hsu

Ian Foltz

Taruna Arora

Frederick W Jacobsen

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-03-20

Filing date

2011-08-24

Publication date

2013-03-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42224952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000433(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-08-24 Application filed by Amgen Inc filed Critical Amgen Inc

2013-03-27 Publication of TN2011000433A1 publication Critical patent/TN2011000433A1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
General Engineering & Computer Science (AREA)
Orthopedic Medicine & Surgery (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Otolaryngology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Mycology (AREA)

TN2011000433A 2009-03-20 2011-08-24 Alpha -4-beta-7heterodimer specific antagonist antibody TN2011000433A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16215409P	2009-03-20	2009-03-20
US30682910P	2010-02-22	2010-02-22
PCT/US2010/027422 WO2010107752A2 (fr)	2009-03-20	2010-03-16	Anticorps antagoniste spécifique d'un hétérodimère alpha-4-bêta-7

Publications (1)

Publication Number	Publication Date
TN2011000433A1 true TN2011000433A1 (en)	2013-03-27

Family

ID=42224952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2011000433A TN2011000433A1 (en)	2009-03-20	2011-08-24	Alpha -4-beta-7heterodimer specific antagonist antibody

Country Status (26)

Country	Link
US (6)	US8444981B2 (fr)
EP (1)	EP2408816B1 (fr)
JP (3)	JP5498566B2 (fr)
KR (2)	KR101346530B1 (fr)
CN (2)	CN103382222B (fr)
AR (1)	AR075882A1 (fr)
AU (1)	AU2010226814B2 (fr)
CA (2)	CA2754113C (fr)
CL (3)	CL2011002306A1 (fr)
CO (1)	CO6501170A2 (fr)
CR (1)	CR20110544A (fr)
EA (1)	EA034783B1 (fr)
ES (1)	ES2751946T3 (fr)
IL (4)	IL214868A (fr)
JO (1)	JO3615B1 (fr)
MA (1)	MA33213B1 (fr)
MX (4)	MX357213B (fr)
MY (2)	MY162752A (fr)
NZ (1)	NZ595464A (fr)
PE (2)	PE20120497A1 (fr)
SG (3)	SG174344A1 (fr)
TN (1)	TN2011000433A1 (fr)
TW (2)	TWI466681B (fr)
UY (1)	UY32501A (fr)
WO (1)	WO2010107752A2 (fr)
ZA (1)	ZA201107279B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102136208B1 (ko)	2011-05-02	2020-07-21	밀레니엄 파머슈티컬스 인코퍼레이티드	항-α4β7 항체에 대한 제형
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
CA2856866C (fr) *	2011-11-23	2022-07-12	Amgen Inc.	Administration d'un anticorps specifique heterodimere anti-alpha-4-beta-7
WO2014031174A1 (fr)	2012-08-24	2014-02-27	The Regents Of The University Of California	Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la métastase
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US9708375B2 (en)	2013-03-15	2017-07-18	Amgen Inc.	Inhibitory polypeptides specific to WNT inhibitors
EP3041863A4 (fr)	2013-09-05	2017-08-16	Amgen Inc.	Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
CN106062193B (zh)	2014-02-28	2020-08-25	安斯泰来制药株式会社	与人tlr2及人tlr4结合的双特异性抗体
WO2015175861A1 (fr)	2014-05-16	2015-11-19	Amgen Inc.	Dosage pour la détection de populations de cellules th1 et th2
EP3485910A2 (fr)	2014-08-22	2019-05-22	Sorrento Therapeutics, Inc.	Protéines de liaison à un antigène qui se lient à cxcr3
ES2971041T3 (es)	2014-10-06	2024-06-03	Chemocentryx Inc	Terapia combinada de inhibidores del receptor 9 de quimiocina C-C (CCR9) y anticuerpos bloqueadores anti-integrina alfa4beta7 para el tratamiento de la enfermedad inflamatoria intestinal
EP3224280A1 (fr)	2014-11-26	2017-10-04	Millennium Pharmaceuticals, Inc.	Vedolizumab utilisable en vue du traitement de la maladie de crohn fistulisante
MA41636A (fr)	2015-03-06	2018-01-09	Millennium Pharm Inc	Méthode de traitement de la cholangite sclérosante primitive
CA2994412A1 (fr)	2015-07-31	2017-02-09	Memorial Sloan-Kettering Cancer Center	Proteines de liaison d'antigene ciblant cd56 et leurs utilisations
CN113893341B (zh) *	2015-08-11	2025-07-29	国立大学法人大阪大学	抗体
JP2019508448A (ja)	2016-03-14	2019-03-28	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	移植片対宿主病予防の方法
KR102830639B1 (ko)	2016-03-14	2025-07-07	밀레니엄 파머슈티컬스 인코퍼레이티드	이식편대숙주 질환을 치료하거나 예방하는 방법
AU2017237543B2 (en) *	2016-03-23	2020-02-06	Institut Pasteur Korea	Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same
WO2017165742A1 (fr)	2016-03-24	2017-09-28	Millennium Pharmaceuticals, Inc.	Procédés de traitement d'événements indésirables liés à l'immunité gastro-intestinale dans des polythérapies anti-ctla4 et anti-pd-1
US11760803B2 (en)	2016-03-24	2023-09-19	Takeda Pharmaceutical Company Limited	Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
SG11201808821WA (en)	2016-04-18	2018-11-29	Celldex Therapeutics Inc	Agonistic antibodies that bind human cd40 and uses thereof
JP7202893B2 (ja)	2016-06-12	2023-01-12	武田薬品工業株式会社	炎症性腸疾患を治療する方法
TWI767915B (zh)	2016-06-27	2022-06-21	加州大學董事會	Ror-1與btk拮抗劑的組合
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
JP2020517671A (ja)	2017-04-28	2020-06-18	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	小児の障害を処置する方法
WO2019191150A1 (fr)	2018-03-26	2019-10-03	Amgen Inc.	Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
WO2021062372A1 (fr)	2019-09-26	2021-04-01	Amgen Inc.	Procédés de production de compositions d'anticorps
EP4245373A3 (fr)	2020-02-26	2023-12-20	VIR Biotechnology, Inc.	Anticorps contre le sars-cov-2
EP4162257A1 (fr)	2020-06-04	2023-04-12	Amgen Inc.	Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
MX2023004364A (es)	2020-10-15	2023-05-03	Amgen Inc	Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
KR20240006505A (ko) *	2021-03-12	2024-01-15	이칸 스쿨 오브 메디슨 엣 마운트 시나이	Bk 바이러스에 대한 중화 단클론성 항체
MX2023014515A (es)	2021-06-07	2024-01-29	Amgen Inc	Uso de fucosidasa para controlar el nivel de afucosilacion de proteinas glucosiladas.
AU2022361382A1 (en)	2021-10-05	2024-03-28	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (fr)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions et méthodes pour l'immunothérapie cellulaire
WO2024220916A1 (fr)	2023-04-20	2024-10-24	Amgen Inc.	Procédés de détermination de teneur relative en glycane non apparié
AU2024282654A1 (en)	2023-05-30	2025-12-04	Paragon Therapeutics, Inc.	Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (fr)	2023-06-09	2024-12-12	Takeda Pharmaceutical Company Limited	Procédés et compositions pour le traitement de la rectocolite hémorragique
WO2025038600A1 (fr)	2023-08-14	2025-02-20	Amgen Inc.	Procédés de réduction de couleur jaune
WO2025101820A1 (fr)	2023-11-08	2025-05-15	Fred Hutchinson Cancer Center	Compositions et méthodes pour l'immunothérapie cellulaire

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US714785A (en)	1901-07-03	1902-12-02	Benjamin M Davis	Disinfecting apparatus.
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4751180A (en)	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
US4935233A (en)	1985-12-02	1990-06-19	G. D. Searle And Company	Covalently linked polypeptide cell modulators
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5011912A (en)	1986-12-19	1991-04-30	Immunex Corporation	Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de)	1990-08-29	1997-09-15	Genpharm Int	Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
EP0557300B1 (fr)	1990-10-29	1997-11-19	Chiron Corporation	Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
CA2103059C (fr)	1991-06-14	2005-03-22	Paul J. Carter	Methode de production d'anticorps humanises
WO1994004679A1 (fr)	1991-06-14	1994-03-03	Genentech, Inc.	Procede pour fabriquer des anticorps humanises
US5262522A (en)	1991-11-22	1993-11-16	Immunex Corporation	Receptor for oncostatin M and leukemia inhibitory factor
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5869619A (en)	1991-12-13	1999-02-09	Xoma Corporation	Modified antibody variable domains
DK0672141T3 (da)	1992-10-23	2003-06-10	Immunex Corp	Fremgangsmåder til fremstilling af opløselige, oligomere proteiner
US5457035A (en)	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
DK0804237T3 (da)	1994-01-25	2006-10-16	Elan Pharm Inc	Humaniserede antistoffer mod leukocyt-adhæsionsmolekyle VLA-4
US5840299A (en) *	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) *	1994-01-25	2008-10-14	Elan Pharaceuticals, Inc.	Humanized anti-VLA4 immunoglobulins
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US7147851B1 (en) *	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
GB9722131D0 (en)	1997-10-20	1997-12-17	Medical Res Council	Method
CA2341029A1 (fr)	1998-08-17	2000-02-24	Abgenix, Inc.	Production de molecules modifiees avec demi-vie serique prolongee
AU7676300A (en) *	1999-10-12	2001-04-23	Cambridge Antibody Technology Limited	Human anti-adipocyte monoclonal antibodies and their use
GB9928787D0 (en)	1999-12-03	2000-02-02	Medical Res Council	Direct screening method
US20010046496A1 (en) *	2000-04-14	2001-11-29	Brettman Lee R.	Method of administering an antibody
GB0025144D0 (en)	2000-10-13	2000-11-29	Medical Res Council	Concatenated nucleic acid sequences
JPWO2002078779A1 (ja) *	2001-03-27	2004-07-22	日本ゼオン株式会社	医療用ガイドワイヤ
AU2002254431A1 (en) *	2001-03-27	2002-10-08	M. Eric Gershwin	Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2004016769A2 (fr)	2002-08-19	2004-02-26	Abgenix, Inc.	Anticorps diriges contre la proteine chimioattractive monocytaire 1 (mcp-1) et leurs utilisations
US20040202995A1 (en)	2003-04-09	2004-10-14	Domantis	Nucleic acids, proteins, and screening methods
AR047372A1 (es) *	2004-01-09	2006-01-18	Pfizer	Anticuerpos contra madcam
US7329737B2 (en)	2004-08-03	2008-02-12	Dyax Corp.	Antibodies that bind hK-1
US20070098715A1 (en)	2005-03-25	2007-05-03	Seth Ettenberg	Antibodies against the tenascin major antigens
US7480268B2 (en)	2005-07-28	2009-01-20	Symbol Technologies, Inc.	System and method for multiprotocol wireless communication
CA2629147A1 (fr)	2005-11-17	2007-05-31	Millennium Pharmaceuticals, Inc.	Immunoglobuline humanisee reactive avec l'integrine .alpha.4.beta.7
US7910703B2 (en) *	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use

2010
- 2010-03-16 MX MX2016001889A patent/MX357213B/es unknown
- 2010-03-16 KR KR1020117024649A patent/KR101346530B1/ko active Active
- 2010-03-16 WO PCT/US2010/027422 patent/WO2010107752A2/fr not_active Ceased
- 2010-03-16 CN CN201310216898.1A patent/CN103382222B/zh active Active
- 2010-03-16 TW TW99107689A patent/TWI466681B/zh active
- 2010-03-16 PE PE2011001661A patent/PE20120497A1/es not_active Application Discontinuation
- 2010-03-16 JP JP2012500875A patent/JP5498566B2/ja active Active
- 2010-03-16 SG SG2011065570A patent/SG174344A1/en unknown
- 2010-03-16 US US12/725,031 patent/US8444981B2/en active Active
- 2010-03-16 CN CN201080013557.9A patent/CN102388068B/zh active Active
- 2010-03-16 AU AU2010226814A patent/AU2010226814B2/en active Active
- 2010-03-16 MY MYPI2011004308A patent/MY162752A/en unknown
- 2010-03-16 TW TW103102822A patent/TWI477511B/zh active
- 2010-03-16 EP EP10708688.6A patent/EP2408816B1/fr active Active
- 2010-03-16 MA MA34274A patent/MA33213B1/fr unknown
- 2010-03-16 KR KR1020137012483A patent/KR101391472B1/ko active Active
- 2010-03-16 PE PE2016000333A patent/PE20160553A1/es unknown
- 2010-03-16 EA EA201171148A patent/EA034783B1/ru not_active IP Right Cessation
- 2010-03-16 MX MX2015002115A patent/MX338969B/es unknown
- 2010-03-16 ES ES10708688T patent/ES2751946T3/es active Active
- 2010-03-16 NZ NZ595464A patent/NZ595464A/xx unknown
- 2010-03-16 CA CA2754113A patent/CA2754113C/fr active Active
- 2010-03-16 SG SG10201400798VA patent/SG10201400798VA/en unknown
- 2010-03-16 CA CA2851737A patent/CA2851737C/fr active Active
- 2010-03-16 MX MX2011009897A patent/MX2011009897A/es active IP Right Grant
- 2010-03-16 SG SG10201801337WA patent/SG10201801337WA/en unknown
- 2010-03-16 MY MYPI2015002744A patent/MY184957A/en unknown
- 2010-03-16 MX MX2014013424A patent/MX357211B/es active IP Right Grant
- 2010-03-18 JO JOP/2010/0090A patent/JO3615B1/ar active
- 2010-03-18 AR ARP100100867A patent/AR075882A1/es active IP Right Grant
- 2010-03-18 UY UY0001032501A patent/UY32501A/es not_active Application Discontinuation
2011
- 2011-08-24 TN TN2011000433A patent/TN2011000433A1/fr unknown
- 2011-08-29 IL IL214868A patent/IL214868A/en active IP Right Grant
- 2011-09-16 CL CL2011002306A patent/CL2011002306A1/es unknown
- 2011-09-30 CO CO11128767A patent/CO6501170A2/es not_active Application Discontinuation
- 2011-10-05 ZA ZA2011/07279A patent/ZA201107279B/en unknown
- 2011-10-18 CR CR20110544A patent/CR20110544A/es unknown
2012
- 2012-03-22 US US13/427,745 patent/US8454961B2/en not_active Expired - Fee Related
- 2012-03-22 US US13/427,757 patent/US8454962B2/en not_active Expired - Fee Related
2013
- 2013-04-22 US US13/867,498 patent/US8871490B2/en active Active
2014
- 2014-02-18 CL CL2014000400A patent/CL2014000400A1/es unknown
- 2014-02-18 CL CL2014000401A patent/CL2014000401A1/es unknown
- 2014-03-06 JP JP2014043790A patent/JP5775615B2/ja active Active
- 2014-04-08 IL IL232009A patent/IL232009A/en active IP Right Grant
- 2014-04-08 IL IL232008A patent/IL232008A/en active IP Right Grant
- 2014-09-26 US US14/497,883 patent/US9499620B2/en active Active
2015
- 2015-07-03 JP JP2015134473A patent/JP5980384B2/ja active Active
- 2015-07-16 IL IL239965A patent/IL239965A/en active IP Right Grant
2016
- 2016-11-09 US US15/347,233 patent/US20170275365A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SG174344A1 (en)	2011-11-28
JP5980384B2 (ja)	2016-08-31
ZA201107279B (en)	2012-12-27
IL232008A (en)	2015-11-30
CL2011002306A1 (es)	2012-01-13
US20120183561A1 (en)	2012-07-19
IL239965A0 (en)	2015-08-31
CN102388068A (zh)	2012-03-21
US8454961B2 (en)	2013-06-04
TW201418281A (zh)	2014-05-16
IL232008A0 (en)	2014-05-28
MA33213B1 (fr)	2012-04-02
TW201036626A (en)	2010-10-16
WO2010107752A2 (fr)	2010-09-23
MX357213B (es)	2018-06-29
MY184957A (en)	2021-04-30
JP5775615B2 (ja)	2015-09-09
MX2011009897A (es)	2011-12-08
US20130302354A1 (en)	2013-11-14
KR20130067314A (ko)	2013-06-21
CA2754113C (fr)	2014-08-05
US20170275365A1 (en)	2017-09-28
KR101391472B1 (ko)	2014-05-07
MX2014013424A (es)	2015-07-29
CA2851737C (fr)	2019-01-08
CO6501170A2 (es)	2012-08-15
CL2014000401A1 (es)	2014-08-29
US20150086563A1 (en)	2015-03-26
JP5498566B2 (ja)	2014-05-21
CN102388068B (zh)	2015-05-20
CN103382222B (zh)	2016-12-28
AU2010226814A1 (en)	2011-09-29
JO3615B1 (ar)	2020-08-27
ES2751946T3 (es)	2020-04-02
KR20110128948A (ko)	2011-11-30
PE20160553A1 (es)	2016-05-18
US8454962B2 (en)	2013-06-04
MX357211B (es)	2018-06-29
MY162752A (en)	2017-07-14
IL232009A (en)	2015-11-30
US20100254975A1 (en)	2010-10-07
NZ595464A (en)	2013-08-30
KR101346530B1 (ko)	2013-12-31
US8871490B2 (en)	2014-10-28
AU2010226814B2 (en)	2013-05-16
IL239965A (en)	2016-10-31
SG10201400798VA (en)	2014-07-30
EA034783B1 (ru)	2020-03-20
US20120177662A1 (en)	2012-07-12
CN103382222A (zh)	2013-11-06
JP2014140372A (ja)	2014-08-07
EP2408816B1 (fr)	2019-09-04
AR075882A1 (es)	2011-05-04
UY32501A (es)	2010-04-30
CA2851737A1 (fr)	2010-09-23
CR20110544A (es)	2011-12-07
TWI477511B (zh)	2015-03-21
US9499620B2 (en)	2016-11-22
EP2408816A2 (fr)	2012-01-25
JP2012520679A (ja)	2012-09-10
IL214868A0 (en)	2011-11-30
WO2010107752A3 (fr)	2011-01-20
CL2014000400A1 (es)	2014-08-29
HK1168116A1 (en)	2012-12-21
IL232009A0 (en)	2014-05-28
JP2015214563A (ja)	2015-12-03
PE20120497A1 (es)	2012-05-14
EA201171148A1 (ru)	2012-04-30
MX338969B (es)	2016-05-06
IL214868A (en)	2015-08-31
TWI466681B (zh)	2015-01-01
SG10201801337WA (en)	2018-03-28
CA2754113A1 (fr)	2010-09-23
US8444981B2 (en)	2013-05-21

Publication	Publication Date	Title
TN2011000433A1 (en)	2013-03-27	Alpha -4-beta-7heterodimer specific antagonist antibody
MX382398B (es)	2025-03-13	Proteinas de union a antigeno st2.
WO2010145792A8 (fr)	2011-10-06	Protéines bispécifiques se liant à un antigène
MX2015008446A (es)	2016-10-26	Composiciones de proteinas de union multivalentes.
IL216620A0 (en)	2012-02-29	Bispecific, tetravalent antigen binding proteins
PH12013502205A1 (en)	2015-10-12	Antibodies to il-6 and their uses
ZA201207211B (en)	2014-06-25	Antibodies with ph dependent antigen binding
SG10201401681PA (en)	2014-07-30	Novel antigen binding proteins
TN2014000120A1 (en)	2015-07-01	Cd27l antigen binding proteins
EP2552967A4 (fr)	2014-10-08	Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
TN2016000067A1 (en)	2017-07-05	Antibodies
MX340683B (es)	2016-07-21	Anticuerpos anti-vla-4.
PH12015500752A1 (en)	2015-05-25	Her3 antigen binding proteins binding to the beta-hairpin of her3
PH12015500751A1 (en)	2015-05-25	Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and beta-hairpin of her4
WO2010136483A3 (fr)	2011-01-20	Protéines de liaison à l'antigène
WO2013181576A3 (fr)	2014-03-13	Méthodes d'évaluation et de fabrication de produits biologiques
UA104311C2 (ru)	2014-01-27	Антитело-антагонист, специфическое для гетеродимера альфа-4-бета-7
IL266073B (en)	2021-10-31	Proteins comprising heterodimeric antibody fc and methods for their preparation
WO2012122125A3 (fr)	2013-01-31	Compositions et procédés ciblant la génération de force dans les kinésines
HK1186740A (en)	2014-03-21	Novel antigen binding proteins